Brolucizumab vs aflibercept and ranibizumab for neovascular age-related macular degeneration: A cost-effectiveness analysis

Medicine & Life Sciences

• aflibercept 67%
• Blindness 8%
• brolucizumab 100%
• Cost-Benefit Analysis 39%
• Costs and Cost Analysis 16%
• Developed Countries 2%
• Diabetic Retinopathy 3%
• Drug Costs 6%
• Endothelial Growth Factors 4%
• Health 1%
• Injections 3%
• Macular Degeneration 48%
• Ocular Vision 2%
• Phase III Clinical Trials 3%
• Quality-Adjusted Life Years 12%
• Ranibizumab 61%
• Therapeutics 4%
• Vascular Endothelial Growth Factor A 2%
• Visual Acuity 7%

Chemistry

• Antivascular 21%
• Drug 12%
• Growth Factor 13%
• Time 16%
• Time Schedule of Dosing 22%
• Vasculotropin Inhibitor 23%

Social Sciences

• blindness 12%
• cause 4%
• Clinical Trials 3%
• costs 25%
• death 2%
• drug 4%
• health 1%
• life years 18%
• monitoring 5%
• scenario 2%
• time 4%